ChartRow logo
Data provided bySource: Twelve Data
GMED
$69.99-0.72%
as of close, Nov 17, 2026
☾ AH $69.99 -0.72%
PeersSNNPODDZBHSTEBIOPEN
Share this page

GMED financial statements

The full income statement, balance sheet, and cash-flow statement for Globus Medical Inc. (GMED), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +30.1%10Y CAGR +18.4%YoY −0.7%
$3.1B TTM$763.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +28.2%10Y CAGR +17.0%YoY +2.8%
$2.2B TTM$530.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +33.9%10Y CAGR +10.8%YoY +29.3%
$679.7M TTM$177.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +39.4%10Y CAGR +16.9%YoY +18.7%
$557.6M TTM$141.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +31.2%10Y CAGR +12.9%YoY +18.2%
$4.07 TTM$1.04 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +30.5%10Y CAGR +19.8%YoY +6.2%
$925.9M TTM$265.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR +20.9%10Y CAGR +12.5%YoY +12.8%
$159.4M TTM$40.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +34.2%10Y CAGR +23.2%YoY +5.1%
$766.5M TTM$224.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +35.7%10Y +42.7%YoY +0.5%
137M TTM136M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q3 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every GMED chart on Trends →

Shares outstanding (point-in-time)

2024-09 136.2M2024-12 137.5M2025-03 135.4M2025-06 135.1M2025-09 133.8M2025-12 135.3M2026-03 135.7M2026-06 134.3M2026-09 132.5M-2.7% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue2.94B+16.7%2.52B+60.6%1.57B+53.3%1.02B+6.8%958M+21.4%
1.98B+33.5%1.48B+45.4%1.02B+34.4%759M+5.6%719M+25.8%
Cost of revenue958M-7.5%1.04B+88.9%548M+107.9%264M+10.2%239M+10.0%
2.46B+4.5%2.35B+165.3%887M+67.0%531M-2.9%547M+18.9%
Research & development147M-10.1%164M+32.0%124M+69.8%73.0M-25.0%97.3M+15.2%
Selling, general & administrative1.18B+20.1%981M+52.4%644M+49.0%432M+5.9%408M+15.1%
Restructuring
—29.7M———
Amortization of intangibles118M-1.0%119M+133.9%51.0M+187.7%17.7M-4.3%18.5M+10.1%
Provision for credit losses10.2M-39.8%17.0M+364.4%3.66M+365900.0%-1.00K-100.1%1.20M-59.5%
Operating income480M+189.1%166M+24.7%133M-41.6%228M+32.6%172M+54.3%
Net interest income—-4.19M-120.8%20.1M+41.4%14.2M+53.1%9.30M-33.4%
Other non-operating income3.41M+54.8%2.21M+203.1%-2.14M-215.3%1.85M-78.1%8.45M-41.6%
Pre-tax income605M+401.2%121M-27.0%165M-31.9%243M+34.7%180M+43.3%
Income tax67.2M+278.8%17.7M-58.3%42.5M-19.5%52.9M+69.3%31.2M+32.2%
538M+422.3%103M-16.2%123M-35.4%190M+27.5%149M+45.9%
Net income to common538M+422.3%103M-16.2%123M-35.4%190M+27.5%149M+45.9%
$3.92+422.7%$0.75-29.9%$1.07-42.2%$1.85+28.5%$1.44+42.6%
EPS (basic)$3.98+423.7%$0.76-30.3%$1.09-42.3%$1.89+27.7%$1.48+42.3%
Weighted-avg shares (basic)135M-0.4%136M+20.0%113M+12.6%100M-0.3%101M+2.2%
Weighted-avg shares (diluted)137M-0.6%138M+20.3%115M+11.7%103M-0.9%104M+2.6%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
2.13B-2.4%2.18B+13.7%1.92B+94.8%983M+13.7%865M+5.2%
Cash & equivalents526M-32.9%784M+67.9%467M+210.6%150M-22.1%193M-19.4%
Short-term investments31.1M-70.6%106M+109.2%50.5M-82.9%296M+18.1%250M+33.6%
Accounts receivable679M+21.7%558M+10.8%503M+136.0%213M+29.7%164M+16.1%
Inventory759M+15.2%659M-22.3%848M+183.7%299M+26.2%237M+3.4%
Prepaid expenses65.4M+31.8%49.6M+11.4%44.6M+112.3%21.0M+14.0%18.4M+3.6%
5.30B+1.0%5.25B+3.3%5.09B+145.0%2.08B+6.1%1.96B+16.5%
Property, plant & equipment564M+0.5%562M-4.3%587M+140.8%244M+10.2%221M+1.9%
Operating lease right-of-use63.8M+28.5%49.6M-17.2%59.9M+900.9%5.99M+19.3%5.02M+5.9%
Goodwill1.44B+0.2%1.43B-0.2%1.43B+626.5%197M+9.9%180M+14.7%
Intangible assets745M-6.3%795M-14.0%925M+1354.4%63.6M-7.4%68.7M-21.0%
Long-term investments71.8M+8.6%66.1M-12.3%75.4M-84.8%496M-11.8%562M+56.9%
Deferred tax assets218M+131.7%94.2M+781.6%10.7M-78.1%48.8M+99.4%24.5M+270.3%
Other non-current assets78.8M+4.9%75.1M-4.4%78.6M+110.6%37.3M+2.7%36.3M+13.4%
498M-41.8%856M+118.2%392M+146.4%159M+13.6%140M+16.0%
Accounts payable98.9M+31.6%75.1M+32.6%56.7M+57.0%36.1M+64.4%22.0M+20.6%
Accrued liabilities334M+28.0%261M+8.4%240M+160.9%92.2M+1.1%91.2M+16.4%
Deferred revenue27.7M+24.9%22.1M+20.5%18.4M+30.3%14.1M+17.3%12.0M+48.0%
Short-term & current debt0.00-100.0%443M———
Current lease liability14.7M+43.8%10.2M-14.4%12.0M+371.9%2.54M+19.8%2.12M+13.5%
Finance lease liability (current)348K+49.4%233K-50.9%475K——
730M-32.1%1.07B-1.3%1.09B+373.6%230M+6.4%216M+24.6%
Long-term debt
——417M——
Non-current lease liability104M+24.3%83.6M-8.2%91.0M+2519.8%3.48M+18.3%2.94M+0.0%
Operating lease liability (total)119M+26.4%93.8M-8.9%103M—5.05M+5.2%
Finance lease liability (total)784K+47.6%531K-34.6%812K——
Finance lease liability436K+46.3%298K-11.6%337K——
Deferred tax liabilities—23.9M-71.7%84.4M+4645.4%1.78M-58.8%4.31M-30.4%
Other non-current liabilities21.3M-0.9%21.5M-12.5%24.6M+137.8%10.3M-18.2%12.6M-14.0%
4.57B+9.5%4.18B+4.5%4.00B+116.5%1.85B+6.0%1.74B+15.6%
Additional paid-in capital3.17B+4.6%3.03B+5.6%2.87B+355.0%631M+13.9%554M+21.1%
Retained earnings1.39B+20.4%1.15B+1.4%1.14B-8.3%1.24B+3.8%1.19B+14.3%
Accumulated other comprehensive income15.3M+323.7%-6.86M+32.7%-10.2M+58.6%-24.6M-263.7%-6.77M-271.2%
Total equity incl. non-controlling4.57B+9.5%4.18B+4.5%4.00B+116.5%1.85B+6.0%1.74B+15.6%
Total liabilities & equity5.30B+1.0%5.25B+3.3%5.09B+145.0%2.08B+6.1%1.96B+16.5%
Shares outstanding (cover)135M-1.7%138M+1.6%135M+35.0%100M-1.2%102M+1.8%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
753M+44.7%521M+113.8%243M+36.4%178M-35.4%276M+39.0%
Depreciation & amortization277M+9.3%253M+74.1%146M+113.2%68.3M-2.3%69.9M+11.1%
Intangible amortization118M-1.0%119M+133.9%51.0M+187.7%17.7M-4.3%18.5M+10.1%
Share-based compensation49.8M-8.1%54.2M+2.7%52.7M+60.7%32.8M+7.3%30.6M+13.0%
Deferred income taxes—-134M-130.1%-58.2M-160.9%-22.3M-26.5%-17.6M-347.8%
Change in receivables52.2M-33.2%78.1M+56.4%49.9M-1.8%50.8M+96.3%25.9M+342.1%
Change in inventory17.6M-41.1%29.9M-57.5%70.3M+13.9%61.7M+415.8%12.0M-76.1%
Change in payables8.49M-52.0%17.7M+224.2%-14.2M-198.6%14.4M+291.4%3.68M+158.0%
-355M-101.7%-176M-158.1%303M+374.5%-110M+70.6%-376M-220.4%
Capital expenditure165M+42.7%115M+47.5%78.3M+5.7%74.0M+30.1%56.9M-10.6%
Free cash flow589M+45.3%405M+145.2%165M+58.2%104M-52.4%219M+62.3%
Acquisitions253M+1332.1%17.6M-94.0%296M+841.7%31.4M-8.9%34.5M+3.0%
Purchases of investments—114M+12.8%101M-76.0%420M-32.6%622M+178.4%
Sales/maturities of investments63.9M+8.9%58.7M-75.6%240M-23.1%312M+37.0%228M+69.5%
-679M-2352.2%-27.7M+88.1%-232M-110.8%-110M-303.1%54.1M+240.0%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.000.000.000.000.00
Common stock repurchased300M+250.2%85.8M-62.0%226M+56.1%144M0.00-100.0%
Dividends paid0.000.000.000.000.00
FX effect on cash22.4M+8702.0%255K-88.3%2.18M+391.8%-747K+7.8%-810K-193.6%
Net change in cash-258M-181.4%317M+0.1%317M+843.7%-42.6M+8.0%-46.3M-206.1%
Income taxes paid98.9M-37.6%159M+57.6%101M+29.3%77.8M+72.8%45.0M+77.0%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap11.8B+3.8%11.4B+85.2%6.14B-17.2%7.42B+1.1%7.33B+12.7%
P/E22.0×-80.1%110.5×+184.0%38.9×-18.6%47.8×-2.8%49.1×-22.8%
P/S4.0×-11.0%4.5×-9.8%5.0×-32.6%7.4×-2.9%7.7×-7.2%
P/B2.6×-5.2%2.7×+85.7%1.5×-65.1%4.2×-0.2%4.2×-2.6%
P/FCF20.1×-28.6%28.1×-41.0%47.6×-24.3%62.8×+88.0%33.4×-30.6%
Earnings yield4.6%+403.1%0.91%-64.8%2.6%+22.8%2.1%+2.9%2.0%+29.5%
FCF yield5.0%+40.0%3.6%+69.5%2.1%+32.1%1.6%-46.8%3.0%+44.1%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Daniel Scavilla $5.3M / −$5.7MKeith Pfeil $4.4M / $5M$9.7M−$742K$2.7M$134.00$127.00
FY2024Daniel Scavilla$4.9M$9.5M$2.4M$127.00$117.00
FY2023Daniel Scavilla$4.6M$1.9M$2.3M$82.00$106.00
FY2022Daniel Scavilla $3.8M / $4.2MDavid Demski $4.7M / −$4.5M$8.6M−$292.6K$1.8M$114.00$97.00
FY2021David Demski$5.1M$7.7M$1.6M$111.00$119.00
FY2020David Demski$4M$5.5M$1.7M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: GMED’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all GMED filings on SEC EDGAR → Not investment advice.